Haemonetics Corp. (NYSE: HAE) reported Q2 EPS of $0.72, $0.76 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $179.4 million versus the consensus estimate of $173.55 million.

Haemonetics Corp. sees FY2011 EPS of $3.00-$3.10, versus the consensus of $3.38.

Earnings Guidance